Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176343 | 0.85 | ENPP2 (0.46) | MAPTPOLBTP53KMT2ALMNA | |
| SCHEMBL4882490 | 0.84 | TSHR (0.49) | MAPTPOLBTP53KMT2ANPC1 | |
| SCHEMBL4881920 | 0.84 | TP53 (0.47) | MAPTTP53KMT2ASMN1; SMN2LMNA | |
| SCHEMBL24176322 | 0.84 | ENPP2 (0.49) | KMT2AENPP2MEN1 | |
| SCHEMBL3145312 | 0.80 | MAPT (0.49) | MAPTPOLBKMT2ANPC1RAB9A | |
| SCHEMBL1094177 | 0.75 | PTGS2 (0.47) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL11699718 | 0.75 | PTGS2 (0.47) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4931956 | 0.73 | POLB (0.44) | MAPTPOLBTP53KMT2ANPC1 | |
| SCHEMBL24176474 | 0.69 | PDE2A (0.47) | LMNAENPP2 | |
| SCHEMBL3087806 | 0.64 | NPC1 (0.44) | MAPTKMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022003377-A1 | THIENO[3,4-C]PYRAZOL-3-YL ACETAMIDES AS AUTOTAXIN INHIBITORS | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2022-01-06 | — | — | WO | disclosed |
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| WO-2014078322-A1 | THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| CN-103649076-A | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | ARRAY BIOPHARMA INC | 2014-03-19 | — | — | CN | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | US | disclosed |
| CN-101084223-A | Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| EP-1831228-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068591-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | MAPT 464/4885POLB 1290/4885TP53 214/4885 |
| US-20080081833-A1 | Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors | CHRM2, CHRNA1, CHRM1 | MAPT 1368/4885POLB 4467/4885TP53 3427/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | MAPT 118/4885POLB 1201/4885TP53 369/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MAPT 464/4885POLB 1290/4885TP53 214/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MAPT 464/4885POLB 1290/4885TP53 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.